Employees: 22
Size Entera Bio (ENTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $568M, the 2581st largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.26 on 18 Nov 2026.
Performance Over six months the shares gained 162.9%, against -21.2% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue fell 100.0% over the last twelve months (peer median +4.6%).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $42,000 | $181,000 | $0 | $134,000 |
| Revenue growth | — | -77% | — | -100% | — |
| Gross profit | -$32,000 | -$30,000 | $9,000 | -$56,000 | -$31,000 |
| EBITDA | -$18.4M | -$11.5M | -$9.54M | -$8.88M | -$13.0M |
| Net income | -$29.4M | -$11.4M | -$9.54M | -$8.89M | -$13.1M |
| Free cash flow | -$16.1M | -$7.48M | -$6.82M | -$7.33M | -$12.5M |
| Capital expenditure | $53,921 | $107,000 | $3,000 | $17,000 | $47,000 |
| Total debt | $397,000 | $490,000 | $272,000 | $390,000 | $91,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ENTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.0% | -11.4% | 2nd highest of 21 |
| 6-month return | +162.9% | -21.2% | highest of 21 |
| Distance from 52-week high | -22.4% | -42.9% | 3rd highest of 21 |
| Revenue growth (TTM) | -100.0% | +4.6% | lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Entera Bio ENTX | United States | $568M | +163% | -100% | n/a | n/a | n/a | n/a |
| Alumis ALMS | United States | $569M | -80% | -67% | -5,375% | 23.9× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $563M | -30% | +52% | 11% | 8.7× | 36.4% | +11.2% |
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | 6.2× | n/a | n/a |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $577M | -26% | -21% | 32% | 1.9× | -15.4% | +2.8% |
| Abbisko Cayman 2256.HK | Hong Kong | $578M | -39% | -83% | -520% | 20.1× | n/a | n/a |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 1.2× | -5.8% | +4.1% |
| Oneness Biotech 4743.TWO | Taiwan | $580M | -13% | +19% | -589% | 101.5× | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $580M | -43% | +47% | 7% | 4.5× | n/a | n/a |
| Aclaris Therapeutics ACRS | United States | $555M | -23% | -59% | -1,412% | 69.1× | n/a | n/a |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 0.9× | -3.1% | +12.6% |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $583M | -20% | -6% | 5% | 2.6× | 20.9% | +21.9% |
| Zevra Therapeutics ZVRA | United States | $552M | -9% | +75% | 31% | 2.4× | -4.9% | +51.6% |
| Zeria Pharmaceutical 4559.T | Japan | $552M | -12% | +12% | 15% | 1.0× | -12.3% | +11.1% |
| Cullinan Therapeutics CGEM | United States | $585M | -37% | n/a | n/a | n/a | n/a | n/a |
| Jinhe Biotechnology 002688.SZ | China | $550M | -19% | +7% | 5% | 1.8× | 1.0% | +9.7% |
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | 3.7× | 50.4% | -12.3% |
| Morepen Laboratories MOREPENLAB.NS | India | $542M | +121% | +30% | 11% | 2.2× | n/a | n/a |
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 0.9× | -6.2% | +6.5% |
| Senores Pharmaceuticals SENORES.NS | India | $538M | +3% | +40% | 24% | 7.4× | n/a | n/a |